KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Current Deferred Revenue: 2010-2014

Historic Current Deferred Revenue for Biocryst Pharmaceuticals (BCRX) over the last 5 years, with Dec 2014 value amounting to $5.6 million.

  • Biocryst Pharmaceuticals' Current Deferred Revenue rose 41.93% to $2.1 million in Q3 2015 from the same period last year, while for Sep 2015 it was $2.1 million, marking a year-over-year increase of 41.93%. This contributed to the annual value of $5.6 million for FY2014, which is 280.52% up from last year.
  • Latest data reveals that Biocryst Pharmaceuticals reported Current Deferred Revenue of $5.6 million as of FY2014, which was up 280.52% from $1.5 million recorded in FY2013.
  • Biocryst Pharmaceuticals' Current Deferred Revenue's 5-year high stood at $9.8 million during FY2011, with a 5-year trough of $1.4 million in FY2012.
  • In the last 3 years, Biocryst Pharmaceuticals' Current Deferred Revenue had a median value of $1.5 million in 2013 and averaged $2.8 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first skyrocketed by 291.91% in 2011, then slumped by 85.78% in 2012.
  • Yearly analysis of 5 years shows Biocryst Pharmaceuticals' Current Deferred Revenue stood at $2.5 million in 2010, then skyrocketed by 291.91% to $9.8 million in 2011, then tumbled by 85.78% to $1.4 million in 2012, then increased by 5.82% to $1.5 million in 2013, then spiked by 280.52% to $5.6 million in 2014.